Altimmune Inc [ALT] stock is trading at $3.71, up 1.09%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALT shares have gain 5.10% over the last week, with a monthly amount glided 1.64%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
On January 08, 2025, Stifel initiated with a Buy rating and assigned a price target of $18 on the stock. UBS started tracking the stock assigning a Buy rating and suggested a price target of $26 on November 12, 2024. Guggenheim downgraded its rating to a Neutral. Goldman started tracking with a Neutral rating for this stock on January 24, 2024, and assigned it a price target of $13. In a note dated March 22, 2023, Goldman downgraded a Neutral rating on this stock and revised its target price from $20 to $6.
Altimmune Inc [ALT] stock has fluctuated between $2.90 and $11.16 over the past year. Currently, Wall Street analysts expect the stock to reach $23.6 within the next 12 months. Altimmune Inc [NASDAQ: ALT] shares were valued at $3.71 at the most recent close of the market. An investor can expect a potential return of 536.12% based on the average ALT price forecast.
Analyzing the ALT fundamentals
Gross Profit Margin for this corporation currently stands at -0.5% with Operating Profit Margin at -4718.5%, Pretax Profit Margin comes in at -4421.35%, and Net Profit Margin reading is -4387.3%. To continue investigating profitability, this company’s Return on Assets is posted at -0.46, Equity is -0.63 and Total Capital is -0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.1.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.62 points at the first support level, and at 3.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.82, and for the 2nd resistance point, it is at 3.93.
Ratios To Look Out For
For context, Altimmune Inc’s Current Ratio is 20.41. In addition, the Quick Ratio stands at 20.41 and the Cash Ratio stands at 19.86. Considering the valuation of this stock, the price to sales ratio is 16371.51, the price to book ratio is 1.96.
Transactions by insiders
Recent insider trading involved Sohn Catherine A., Director, that happened on Mar 17 ’25 when 1000.0 shares were purchased. Chief Financial Officer, WEAVER GREGORY L completed a deal on Mar 13 ’25 to buy 10000.0 shares.
